NORMEE Limited(Head office:Chuo-ku,Tokyo, CEO: Eizaburo Iwata, hereinafter refered as "NORMEE") raised fund total of 270 million yen from PEGASUS TECH Ventures (Head office:California, CEO Anis Uzzaman, hereinafter refered as "PEGASUS").
Background of this capital increase is that users don’t want to interact with shared touch-based devices, such as pin pads, touch screens, and fingerprint scanners because of Coronavirus, and Coronavirus is driving the need for contactless biometrics.
Palm Vein Authentication of NORMEE enables users to register their palm vein using their smartphone or tablet without specialized devices, and authenticate their palm vein using a smartphone or tablet at shops without specialized devices. So the users can use biometrics authentication service by non-contact without infection concern to coronavirus.
The purpose of this capital increase is to invest the fund mainly on marketing cost at the foreign countries development mainly in order to meet the surge of global needs to biometrics authentication by the non-contact as measures to coronavirus raging all over the world.
Please feel free to contact us for demonstration, interview etc.